{
    "pmcid": "7870875",
    "qa_pairs": {
        "How does the D614G mutation affect the SARS-CoV-2 spike protein?": [
            "It stabilizes the spike protein trimer and reduces S1 subunit shedding",
            "It increases the affinity for the ACE2 receptor",
            "It causes the spike protein to lose its ability to bind antibodies",
            "It destabilizes the spike protein trimer and increases S1 subunit shedding"
        ],
        "What is the dissociation constant (Kd) of the W25 nanobody for the spike RBD?": [
            "Approximately 0.3 nM",
            "Approximately 3.0 nM",
            "Approximately 30 nM",
            "Approximately 0.03 nM"
        ],
        "What is the primary target of the W25 nanobody developed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The S2 subunit of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2"
        ],
        "What method was used to identify the W25 nanobody with high affinity for the spike protein?": [
            "Bacterial display and a Ficoll density gradient",
            "Yeast display and a sucrose density gradient",
            "Phage display and a cesium chloride gradient",
            "Mammalian cell display and a percoll density gradient"
        ],
        "What potential application is suggested for the W25 nanobody beyond therapeutic use?": [
            "Use in diagnostic assays due to its high specificity and sensitivity",
            "Use in vaccine development to elicit an immune response",
            "Use in gene therapy to correct genetic mutations",
            "Use in antiviral drug development to inhibit viral replication"
        ]
    }
}